Author: Chen, Yiyin; Klein, Sabra L.; Garibaldi, Brian T.; Li, Huifen; Wu, Cunjin; Osevala, Nicole M.; Li, Taisheng; Margolick, Joseph B.; Pawelec, Graham; Leng, Sean X.
Title: Aging in COVID-19: Vulnerability, immunity and intervention Cord-id: mg5wiihj Document date: 2020_10_31
ID: mg5wiihj
Snippet: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic was first reported in Wuhan, China in December 2019, moved across the globe at an unprecedented speed, and has caused a profound and yet still unfolding health and socioeconomic impacts. SARS-CoV-2, a β-coronavirus, is a highly contagious respiratory pathogen that causes a disease that has been termed the 2019 coronavirus disease (COVID-19). Clinical experience thus far indicates that COVID-19 is highly heterogeneous, ran
Document: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic was first reported in Wuhan, China in December 2019, moved across the globe at an unprecedented speed, and has caused a profound and yet still unfolding health and socioeconomic impacts. SARS-CoV-2, a β-coronavirus, is a highly contagious respiratory pathogen that causes a disease that has been termed the 2019 coronavirus disease (COVID-19). Clinical experience thus far indicates that COVID-19 is highly heterogeneous, ranging from being asymptomatic and mild to severe and causing death. Host factors including age, sex, and comorbid conditions are key determinants of disease severity and progression. Aging itself is a prominent risk factor for severe disease and death from COVID-19. We hypothesize that age-related decline and dysregulation of immune function, i.e., immunosenescence and inflammaging play a major role in contributing to heightened vulnerability to severe COVID-19 outcomes in older adults. Much remains to be learned about the immune responses to SARS-CoV-2 infection. We need to begin partitioning all immunological outcome data by age to better understand disease heterogeneity and aging. Such knowledge is critical not only for understanding of COVID-19 pathogenesis but also for COVID-19 vaccine development.
Search related documents:
Co phrase search for related documents- active outbreak and acute increase: 1
- active outbreak and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and adaptive immune protection: 1
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and ade antibody dependent enhancement: 1, 2
- acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and low frequency: 1
- acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- acute ards respiratory distress syndrome and mab monoclonal antibody: 1, 2
- acute increase and adaptive innate: 1, 2
- acute increase and adaptive innate immunity: 1, 2
- acute increase and lung infection: 1, 2, 3, 4, 5, 6, 7, 8
- acute increase and lung infection site: 1
- acute increase and lymphocyte count: 1
Co phrase search for related documents, hyperlinks ordered by date